CURE is an exchange-traded fund — it holds a basket of underlying assets rather than being a single operating company.
Company fundamentals like P/E, revenue, EPS and profit margins don't apply to a fund — its value comes from the assets it holds, not its own earnings. Use the price chart, options and model forecast below for fund-level analysis.
An institutional-grade, numbers-driven thesis on CURE — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 18, 2026, TradersQuant's model rates Direxion Daily Healthcare Bull 3X ETF (CURE) 57/100 with a 12-month base-case forecast of $159.83 — +19.1% versus the current price of $134.25. Direxion Daily Healthcare Bull 3X ETF trades at $134.25 in the Financial Services sector, with a market capitalisation of $191.1M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for CURE is $159.83, implying +19.1% versus the current price. The model's 12-month scenario range runs from $135.62 (bear) to $196.21 (bull), with a base case of $159.83.
CURE currently carries a TradersQuant composite score of 57/100, which we read as a neutral-to-watch signal. Our 12-month price target of $159.83 implies +19.1% from $134.25. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for CURE is $159.83, about +19.1% versus the latest price of $134.25.
TradersQuant's 12-month model forecast for CURE is a base case of $159.83, ranging from $135.62 (bear) to $196.21 (bull), an expected return of +19.1%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for CURE over the next 12 months is $159.83 in the base case (bear $135.62, bull $196.21), versus today's price of $134.25. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for CURE — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates CURE's fair value at $172.37, implying +28.4% of expected upside versus the current price.
Direxion Daily Healthcare Bull 3X ETF does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
